ABSTRACT
INTRODUCTION
The well-established beneficial effects on metabolism of extracts from soy have been attributed to the isoflavones [1] [2] [3] [4] [5] . In agreement with this affirmation we previously demonstrated 6 activation of peroxisome proliferator-activated receptors α by using a methanolic fraction from soybean seeds rich in isoflavones (daidzin, glycitin, genistin, daidzein, malonylglycitin, malonylgenistin, genistein, glycitein, and malonyldaidzin). In addition, several studies reported antidiabetic properties of isoflavones from soy, not only in preclinical models 7, 8 but also in humans 9, 10 . The mechanisms by which isoflavones from soy produce antidiabetic effects include: antioxidant and anti-inflammatory properties 8 protection of beta cells 11 , and stimulation of insulin release 12 . However, there are few studies supporting that this herbal preparations could show acute beneficial effect in diabetes 13 . Moreover, considering that genistein, the main isoflavone present in the soy 14 inhibits alpha-glucosidade 15 , the possibility of an acute effect of extracts of GM on post prandial glycemia should be investigated. Furthermore, there is no dearth of reports evaluating if the inhibition of alpha-glucosidase has pharmacological significance in vivo conditions. Thus, the present study was carried out to verify if the isoflavones from soy would show acute effects on postprandial glycemia.
MATERIALS AND METHODS
PLANT MATERIALS: Capsules (Soyfemme® from Aché Laboratories -Guarulhos, SP, Brazil) containing Isoflavones (40%) from dried extracts of Glycine max (L.) Merr (GM) were used. Immediately before the administration, the contents of the capsules were removed and dissolved in water.
EXPERIMENTAL PROCEDURES: One hundred and thirty male Wistar adult rats (Rattus norvegicus) weighing 250-300g were used. The rats were maintained under controlled temperature (23ºC) and photoperiod (12 h light/12 h dark). All animals received free access to standard commercial laboratory diet (Nuvilab®, Curitiba, PR, Brazil). The manipulation of the animals followed the Brazilian animal protection law. All substances were orally administered through a gastric tube (gavage) in overnight (15-h) fasted rats and blood was collected by decapitation for glucose evaluation 16 .
Acute effect of soluble starch (1000 mg/kg) on glycemia. Glycemia was measured at 0 (baseline values), 5, 10, 15, 20, 30 and 60 min after the administration of soluble starch. We chose the dose of soluble starch on the basis of a previous study 17 . The results are presented in the Figure 1 . 
STATISTICAL ANALYSIS:
The results are reported as means ± standard error of the means (SEM). Significance of differences between the groups was evaluated by Newman-Keuls multiple comparison test. A 95% level of confidence (P<0.05) was accepted for all comparisons.
RESULTS
In the first set of experiments, the acute effect of oral administration of soluble starch on glycemia was investigated. As shown in Figure 1 , elevation (P<0.05) of glycemia was observed from 15 min and this difference was maintained 60 min and 120 min (not showed) later. Because increased (P<0.05) blood glucose was well established 30 min after the administration of soluble starch this time was used in the following experiments. In the second set of experiments, the acute effect of increasing doses of acarbose on the elevation of glycemia promoted by the administration of soluble starch was evaluated. As shown in Figure 2 , the dose of 1.0 mg/kg and 10 mg/kg impair (P<0.05) the elevation of glycemia promoted by soluble starch. Considering that acarbose (10 mg/kg) impaired the elevation of glycemia promoted by the administration of soluble starch this dose was used in the following experiments. In the third set of experiments, the acute effect of increasing doses of GM on the elevation of glycemia promoted by the administration of soluble starch was evaluated. As shown in Figure 3A , the doses of 2.5 mg/kg, 5.0 mg/kg, 7.5 mg/kg, and 10.0 mg/kg decrease (P<0.05) the intensity of elevation of glycemia promoted by soluble starch. Because acarbose prevent 100% the elevation of glycemia we also express the results as percent of effect in comparison with acarbose. Thus, the percent of reduction in the elevation of glycemia after the administration of soluble starch in the groups SS + GM 2.5 mg/kg, SS + GM 5.0 mg/kg, SS + GM 7.5 mg/kg, SS + GM 10.0 mg/kg were 21.8%, 28.8%, 25.4%, and 20%, respectively. Since GM (2.5 mg/kg, 5.0 mg/kg, 7.5 mg/kg, and 10.0 mg/kg) decrease (P<0.05) the intensity of elevation of glycemia promoted by soluble starch, the experiments described in the Figure 3A were repeated again with lower (0.1 mg/kg and 1.0 mg/kg) and higher (100.0 mg/kg) doses of GM. As shown in Figure 3B , the dose of 100.0 mg/kg, but not the doses of 1.0 mg/kg, and 0.1 mg/kg, decrease (P<0.05) the elevation of glycemia promoted by soluble starch. The percent of reduction in the elevation of glycemia after the administration of soluble starch in the groups SS + GM 0.1 mg/kg, SS + GM 1.0 mg/kg, and SS + GM 100.0 mg/kg in comparison with SS + acarbose (100%) were 0%, 0%, and 29.90%, respectively. (Fig.  3A) or GM 0.1, 1.0 and 100 mg/kg (Fig. 3B) in 15-h 
DISCUSSION
An effective strategy for pre diabetes and type 2 diabetes treatments is the inhibition of intestinal α-glucosidase. In this context, acarbose inhibits α-glucosidase from brush border of the small intestine and slows carbohydrate digestion retarding intestinal absorption and thereby reducing postprandial hyperglycemia 18 . However, the undigested carbohydrates are fermented by colonic bacteria causing abdominal distention, flatulence, meteorism and diarrhea. Due to this side effect it is common the abandonment of treatment 19 . Considering that in Brazil there is not another antidiabetic drug with ability to slow intestinal absorption, the possibility of using new compounds instead acarbose has been investigated. In fact there are many in vitro studies showing inhibition of α-glucosidase by isoflavones from plants [20] [21] [22] . However, there is absence of in vivo studies demonstrating antihyperglycemic properties of these compounds. Furthermore, as we previously demonstrated [23] [24] [25] nondiabetic rats represents a suitable pre-clinical model to investigate the impact of oral carbohydrates on post prandial glycemia. Thus, by using this rat model we investigate if dried extracts of GM could reduce the elevation of glycemia promoted by oral ingestion of soluble starch. To the best of our knowledge we demonstrate for the first time the antihyperglycemic properties of GM from in vivo experiments, i.e., the oral administration of GM (2.5 mg/kg, 5.0 mg/kg, 7.5 mg/kg, 10.0 mg/kg and 100.0 mg/kg) decrease (P<0.05) the intensity of elevation of glycemia promoted by soluble starch (Fig. 3A and 3B) . Thus, in agreement with several studies that demonstrated antidiabetic properties to GM [7] [8] [9] [10] [11] [12] [13] we can conclude that isoflavones from dried extracts of GM show acute antihyperglycemic effect. The difference from our results and several studies showing antidiabetic properties for GM is the fact that those evaluations were done after chronic treatment and our evaluation involve acute effects of GM on post prandial glycemia elevation after an oral overload of soluble starch. Thus we concluded that the antidiabetic potential of GM also include acute effects preventing the elevation of post prandial glycemia.
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